Soleno Therapeutics Announces Presentations at ENDO 2022

Rhea-AI Summary

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced participation in ENDO 2022, taking place June 11-14, 2022, in Atlanta, Georgia. The company will present two significant studies on Diazoxide Choline Extended-Release (DCCR) tablets for Prader-Willi Syndrome (PWS). The first is an oral presentation on hormonal and cardiometabolic changes on June 12, 2022, from 11 AM to 12:30 PM ET, presented by Dr. Eric Felner. The second, a poster session on long-term safety, will also occur on June 12, at 1 PM ET, presented by Dr. Michael Woloschak. Presentation materials will be available on the company's website.

Positive

• Participation in ENDO 2022 showcases Soleno's ongoing commitment to research.
• Presentation of two studies highlights advancements in treatment for Prader-Willi Syndrome.

Negative

• None.

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.

Details of the presentations are as follows:

2022 Endocrine Society Meeting (ENDO)

Title:	Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format:	Oral Presentation
Presenter:	Dr. Eric Felner on behalf of the DESTINY PWS Investigators and Soleno Therapeutics
Date:	Sunday, June 12, 2022
Time:	11 AM to 12:30 PM Eastern Time

Title:	Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format:	Poster
Presenter:	Dr. Michael Woloschak on behalf of the DESTINY PWS Investigators and Soleno Therapeutics
Date:	Sunday, June 12, 2022
Time:	1:00 PM ET

The copy of the presentation materials will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

FAQ

What presentations will Soleno Therapeutics have at ENDO 2022?

Soleno will present two studies on Diazoxide Choline Extended-Release (DCCR) tablets for Prader-Willi Syndrome.

When is Soleno's oral presentation at ENDO 2022?

The oral presentation will take place on June 12, 2022, from 11 AM to 12:30 PM ET.

Who will present Soleno's studies at ENDO 2022?

Dr. Eric Felner will present the oral session, and Dr. Michael Woloschak will present the poster.

What time is Soleno's poster presentation at ENDO 2022?

The poster presentation is scheduled for June 12, 2022, at 1 PM ET.

Where can I find the presentation materials from Soleno at ENDO 2022?

The materials will be available in the Investors section on Soleno's website after the presentations.